<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631823</url>
  </required_header>
  <id_info>
    <org_study_id>GBM2018-2020</org_study_id>
    <nct_id>NCT03631823</nct_id>
  </id_info>
  <brief_title>Gut Microbiota and Glioblastoma Multiforme Prognosis</brief_title>
  <official_title>Linking the Gut Microbiota to the Prognosis of Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioma is the most common primary cancer of the central nervous system, and around 50% of
      patients present with the most aggressive form of the disease, glioblastoma. Conventional
      therapies, including surgery, radiotherapy, and pharmacotherapy (typically chemotherapy with
      temozolomide), have not resulted in major improvements in the survival outcomes with only a
      median survival of around 15 months.The main reason may be related to the highly
      immunosuppressive tumor microenvironment. In recent years, the microbiome has emerged as a
      key regulator of not only systemic immune regulation but brain circuitry, neuro-physiology
      and microglia development. We hypothesized that there is a link between the gut microbiota
      and the GBM development and evolution through the immune regulation cells (microglia and
      tumor related macrophagocyte) in the blood circulation to impact the prognosis( PFS and MST)
      of GBM patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We divide the paticipants into three groups. (total number = 200 subjects)

        1. Radio/Chemotherapy group - 80 subjects

        2. Radio/ without chemotherapy group - 70 subjects

        3. Healthy volunteer group - 50 subjects

      After the collection of stools before operation and 3 months after the operaton, we will
      analyze the composition and distribution of gut microbiota, and compare the results of three
      experiment groups.Then we will followe up the patients and analyze the correlation between
      gut microbiota and prognosis of GBM.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-operative gut microbiota in molecular subtype glioblastoma mutiforme multiform</measure>
    <time_frame>12 months</time_frame>
    <description>To analysis the distribution and components of gut microbiota before operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The perturbation of gut microbiota by temozolomide chemotherapy</measure>
    <time_frame>15 months</time_frame>
    <description>To investigate the change of components of gut microbiota induced by chemotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Link the gut microbiota and prognosis of GBM</measure>
    <time_frame>20 months</time_frame>
    <description>To explore the correlation between the gut micriobiota and the prognosis (PFS and MST) by bioinformatic big data process.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gut Microbiota, Glioblastoma Multiforme, Microglia, Tumor Related Macrophagocyte, Prognosis</condition>
  <arm_group>
    <arm_group_label>Radio/Chemotherapy group</arm_group_label>
    <description>The participants in this group receive the concurren radio/chemotrherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radio/ without chemotherapy group</arm_group_label>
    <description>The participants in this group receive the radiotherapy but without chemotrherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <description>The volunteers for control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chemotherapy with temozolomide or no chemotherapy</intervention_name>
    <description>This study is just an observational study.</description>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <arm_group_label>Radio/ without chemotherapy group</arm_group_label>
    <arm_group_label>Radio/Chemotherapy group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      microbiota DNA are extracted from human feces.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients enrolled from neurosurgery department of Huashan hospital and the Shandong
        provincial hospital affiliated to Shandong University; while the healthy volunteers come
        from the health examination center of huashan hospital and Shandong provincial hospital
        affiliated to Shandong University.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The participants diagnosed with glioblastoma multiforme by immunohistochemistry and
        molecular (IDH1, 1p19q, TERT) diagnosis of WHO 2016 classification of Gliomas.

        The healthy volunteers.

        Exclusion Criteria:

          1. No cancer or IBD (inflammatory bowel disease);

          2. No history of abdominal surgery;

          3. No medication related to gastrointestinal motility within 3 months;

          4. No oral antibiotic treatments previous 1 month before neurosurgery operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinsong Wu, Ph.D. &amp; M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weifeng Shi, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taishan Medical Univiersity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yingchao Liu, Ph.D. &amp; M.D</last_name>
    <role>Study Director</role>
    <affiliation>Shandong provincial hospirtal affiliated to Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinsong Wu, Ph.D. &amp; M.D.</last_name>
    <phone>+86-52880000</phone>
    <phone_ext>7220</phone_ext>
    <email>wjsongc@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yingchao Liu, Ph.D. &amp; M.D</last_name>
    <phone>+86-68776128</phone>
    <phone_ext>+8652880000</phone_ext>
    <email>13805311573@126.com</email>
  </overall_contact_backup>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Jinsong Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

